Ertugliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) [3, 4] that is approved by the US Food and Drug Administration and the European Medicines Agency in the EU for the treatment of adults with T2DM [5]. Here, SLC5A2 is linked to type 2 diabetes mellitus.